Gilead Sciences (NASDAQ: GILD) is the leading pharmaceutical company that produces HIV treatments. Its chronic HIV management therapies are largely insulated from macroeconomic downturns because of how crucial they are to those with the disease. Gilead raised its quarterly dividend by 3.8% this year to $0.82, the 11th consecutive year it has increased its dividend. The dividend yield, at Gilead's current share price, is around 1.9%, nearly double the S&P 500 (SNPINDEX: ^GSPC) average. The company has increased its dividend by just under 75% over the past decade. Gilead is in a great position to continue raising its dividend. Let's see why.
CryptoAlerta — análise de criptomoedas e mercado em tempo real